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Abstract 
Introduction. Despite its desirable half-life and low energy Auger electrons that travel 
further than for other radionuclides, 67Ga has been neglected as a therapeutic radionuclide. 
Here, 67Ga is compared with Auger electron emitter 111In as a potential therapeutic 
radionuclide.  
Methods. Plasmid pBR322 studies allowed direct comparison between 67Ga and 111In (1 
MBq) in causing DNA damage, including the effect of chelators (EDTA and DTPA) and the 
effects of a free radical scavenger (DMSO). The cytotoxicity of internalised (by means of 
delivery in the form of oxine complexes) and non-internalised 67Ga and 111In was measured 
in DU145 prostate cancer cells after a one-hour incubation using cell viability (trypan blue) 
and clonogenic studies. MDA-MB-231 and HCC1954 cells were also used. 
Results. Plasmid DNA damage was caused by 67Ga and was comparable to that caused by 
111In; it was reduced in the presence of EDTA, DTPA and DMSO. The A50 values (internalised 
activity of oxine complexes per cell required to kill 50% of cells) as determined by trypan 
blue staining was 1.0 Bq/cell for both 67Ga and 111In; the A50 values determined by clonogenic 
assay were 0.7 Bq/cell and 0.3 Bq/cell for 111In and 67Ga respectively. At the concentrations 
required to achieve these uptake levels, non-internalised 67Ga and 111In caused no cellular 
toxicity. Qualitatively similar results were found for MDA-MB-231 and HCC1954 cells. 
Conclusion. 67Ga causes as much damage as 111In to plasmid DNA in solution and shows 
similar toxicity as 111In at equivalent internalised activity per cell. 67Ga therefore deserves 
further evaluation for radionuclide therapy. 
Advances in Knowledge and Implications for Patient Care. The data presented here is at the 
basic level of science. If future in vivo and clinical studies are successful, 67Ga could become 
a useful radionuclide with little healthy tissue toxicity in the arsenal of weapons for treating 
cancer. 
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1. Introduction 
Radiopharmaceutical therapies, such as 131I-MIBG, anti-CD20 antibodies (labelled with 90Y or 
131I), and 177Lu-Octreotate, have become standard in the clinic. These beta particle-emitting 
treatments, however, are generally not curative and can cause toxicity to healthy tissue due 
to the long range (up to 1 cm for 90Y) by high beta energies. Radioisotopes emitting Auger 
electrons with a much shorter range (<1 μm) are now being considered for targeted 
radionuclide therapy and could become useful tools in targeting micrometastases that play a 
detrimental role in tumour recurrence. 
Gamma camera imaging with 67Ga has been used regularly in the clinic since the 1980s to 
image lymphoma where it was useful in disease staging, monitoring disease progression and 
relapse, and predicting therapy response [1]. In Hodgkin's disease, the detection sensitivity 
is 70 to 83% [2]. In non-Hodgkin's lymphoma the detection sensitivity depends on cell 
differentiation status; less differentiated cells show higher avidity for gallium [1]. Other 
gallium-avid cancers include lung cancer, melanoma and multiple myeloma [1, 2]. In these 
applications 67Ga is administered as 67Ga-citrate and 67Ga uptake by cells is believed to be 
transferrin-mediated [3], although there is also evidence for transferrin-independent 
mechanisms [4-6]. 
A feature of 67Ga is that besides its gamma emissions for scintigraphy and SPECT imaging, it 
also emits Auger electrons [7] and thus has potential as a therapeutic radionuclide. As such 
it could form part of a “theranostic pair” with the generator-produced positron emitter 68Ga. 
Despite producing fewer Auger electrons per decay (average of 4.7) than fellow Auger 
electron emitter 111In (14.7), the average total Auger electron energy released per decay of 
67Ga (6.3 keV) is similar to that of 111In (6.8 keV) [8]. In fact, among Auger electron emitters, 
67Ga produces amongst the most energetic (7 to 9 KeV) and longest ranging (up to 2.4 m in 
water) Auger electrons [7]. This may reduce the need for the radionuclide to be localised in 
specific subcellular compartments in order to be effective.  
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67Ga has been explored previously, to a limited extent, as a radionuclide for therapeutic 
applications [9-13]. In vitro results were promising and showed that treatment with 67Ga 
diminished clonogenic capacity in human U937 lymphoma cells [9] and in myeloid leukemic 
blasts from acute myeloid leukemia patients [10]. A feasibility study in eight patients with 
relapsed acute leukemia was less successful due to the low cell uptake of 67Ga-citrate [11], 
which might have arisen in part from using higher citrate concentrations in the clinical 
preparations than used in the in vitro work.  Others have explored the therapeutic potential 
of 67Ga in lymphoma when coupled to anti-CD74 antibodies [12, 14] or anti-LL1 antibodies 
[13]. Michel et al. showed that 67Ga was two to three times more potent than 111In when 
coupled to anti-CD74 antibodies on the basis of equivalent total disintegrations in the 
medium per viable cell [12]. Low specific activities and lack of purpose-designed gallium 
chelators and conjugates at that time, however, led to a lack of further enquiry in this field.  
In recent years the development of peptides and proteins labelled with 68Ga, arising from 
the growing popularity of the 68Ga generator for positron emission tomography applications, 
has led to a new generation of effective bifunctional chelators for gallium [15-25]. For 
example, the trishydroxypyridinone chelator allows radiolabelling of molecular targeting 
agents with gallium using fast and simple one-step procedures [15, 20]. The resulting 
enhanced versatility and range of potentially useful targeting agents now presents an 
opportunity to reconsider 67Ga as a targeted therapeutic radionuclide.  
Here a comparison is made between 67Ga and the well-characterised and clinically evaluated 
radionuclide 111In, which has been successfully tested preclinically as a therapeutic 
radionuclide attached to cell surface or intracellular targets [26-28]. 67Ga and 111In have 
similar half-lives (78 and 67 hours, respectively) and both produce gamma rays. We used the 
cell-free pBR322 plasmid assay to directly compare DNA damage induced by the 
radionuclides without complications due to cellular and subcellular barriers, DNA repair 
mechanisms and other cellular responses. For the first time, the levels of activity per cell 
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required to achieve significant cytotoxic effects was calculated from viability and clonogenic 
assays using radiolabelled lipophilic complexes in three prostate and breast cancer cell lines, 
selected for their possible future use in in vivo models for radionuclide therapy of circulating 
tumour cells and micrometastases using Auger electron emitters. 
 
2. Materials and methods 
2.1 Radionuclide preparation 
111In-chloride (111InCl3) (Mallinckrodt, Netherlands) was supplied at 111 MBq in 0.3 mL 0.05 
M HCl. 67Ga-citrate (6.46 mM citrate, Mallinckrodt, Netherlands) was converted to 67Ga-
chloride (67GaCl3) [29]. Briefly, 67Ga-citrate (82-160 MBq in 2.2 mL) was diluted to 5 mL with 
dH2O and passed through a Silica Light SEP-PAK column (Waters, US) at 1 mL/min. After 
washing with 5 mL dH2O, trapped 67Ga was eluted with 0.1 M HCl (Sigma, UK) and collected 
in 0.5 mL fractions. Fractions with the highest activity concentration 67Ga-chloride (200-800 
MBq/mL, fractions 6 or 7) were used. 
 
2.2 Cell-free DNA damage by 111In and 67Ga 
125 ng pBR322 (10 μL supplied in 10 mM Tris-HCl (pH 8.0) with 1 mM 
ethylenediaminetetraacetic acid (EDTA), Sigma) was mixed with 1 MBq 111In-chloride, 67Ga-
chloride or 67Ga-citrate and incubated up to 72 hours at 4˚C (final EDTA concentration 0.1 
mM). The final volume was 100 µL in Dulbecco's phosphate-buffered saline pH 7.4 (PBS; 
Thermo Fisher, UK).  
Plasmids were co-incubated with 14 mM dimethylsulfoxide (DMSO), excess EDTA (5 mM) or 
diethylenetriamine pentaacetic acid (DTPA; 5 mM). Controls included untreated plasmid (no 
radionuclide), external irradiation (where radionuclides in a 50 mL tube were physically 
separated from plasmid in 1.5 mL microcentrifuge tube inside the 50 mL tube), and 
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equivalent amounts of non-radioactive gallium- (0.69 pmol) and indium-chloride (0.58 pmol) 
at molar concentrations equivalent to 1 MBq radionuclide. 
After treatment, 12.5 ng plasmid on a 0.8% agarose gel, run at 100V for 25 minutes, was 
visualised with Gel Red™ (Biotium, USA) by UV transilluminator (Gel Doc-it, BioRad, UK). 
 
2.3 Analysis of gel electrophoresis images 
Images were analysed by densitometry of each plasmid band (Figures 1-2, S1-3; supercoiled, 
circular and linear; Image J 1.48, NIH, USA). Background was measured and subtracted from 
band intensity. The fraction of supercoiled plasmid (undamaged) of total plasmid represents 
undamaged plasmid.  
 
2.4 111In- and 67Ga-oxinate complex synthesis 
Lipophilic complexes were prepared from 67Ga citrate as described previously [30]. 67Ga 
citrate (Mallinckrodt Medical Inc, Netherlands; 20-50 MBq, 0.1-1 mL) was added to 50 µg 
oxine (8-hydroxyquinoline; dissolved in ethanol at 1 mg/mL; Sigma). The solution was 
extracted into dichloromethane (Sigma, USA) and this fraction separated and evaporated to 
dryness and reconstituted in 2% ethanol in saline.  
Tropolone (2-hydroxy-2,4,6-cycloheptatriene-1-one) (Sigma) was dissolved in ethanol (1 
mg/mL). MPO (2-mercaptopyridine-N-oxide) (Sigma) was dissolved in distilled water at 1 
mg/mL. 67Ga citrate (Mallinckrodt Medical Inc, Netherlands) was added at 20-50 MBq (0.1-1 
mL) to the ligand solution (50 µg tropolone and 500 µg MPO). The resulting solutions were 
extracted into dichloromethane (Sigma, USA) and measured for labelling yield following 
drying. 
Up to 75 MBq 111In-chloride (0.1 - 0.2 mL), adjusted to pH 6 with acetate buffer, was added 
to oxine (1mg/mL in 2% ethanol) and vortexed for 5 minutes. 111In-oxine complex was 
extracted into chloroform, evaporated and reconstituted in 2% ethanol in saline [31].  
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Radiochemical yield of radiometal complexes was measured in a dose calibrator. 
 
2.5 Cell culture 
Human prostate cancer cells DU145, courtesy of Dr. Florian Kampmeier [32], and breast 
cancer cells HCC1954, were grown in RPMI-1640  at 37 °C in a humidified atmosphere with 
5% CO2. Human breast cancer cells MDA-MB-231 were grown in Dulbecco's Modified Eagle 
Medium (DMEM; with high glucose 4.5 g/L; PAA, Austria). Media were supplemented with L-
glutamine (1.5 mM; PAA Laboratories, Austria), 10% fetal bovine serum (Invitrogen) and 
penicillin (50 I.U./mL)/streptomycin (50 μg/mL) (Invitrogen). Prior to use, cells were 
trypsinised and washed twice with PBS. 
 
2.6 Cellular uptake and retention of radionuclide oxine complexes 
Cells (106) in suspension were incubated with 0.1 MBq 67Ga- or 111In-oxine in 1 mL PBS for 1 
hour at 37 °C and 5% CO2, then pelleted and washed twice with PBS. Cell-bound (pellet) and 
free (supernatant) activity was measured by gamma counter.  
For cellular retention studies, cells were treated and washed as above and plated in a 6-well 
plate for three days. At different times, medium was collected, cells washed, and the 
amount of cell-bound versus free activity measured. The percentage of cell-bound activity 
retained within the cell at time points after 1 hour (set at 100%) was measured. 
 
2.7 Viability assay 
Cells (2.5 x 105) were incubated with 67Ga- (2-25 MBq/mL) or 111In-oxine (0.5-30 MBq/mL) in 
medium (250 μL total) at 37 °C for 1 hour. Oxine and ethanol concentrations were 7 µM and 
1%, respectively. Controls included 67Ga-citrate and 111In-chloride (no significant uptake in 
cells) and decayed oxine complexes at levels equivalent to complete decay of 20 MBq/mL 
samples.  
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Following incubation, cells were centrifuged, washed and seeded in medium in 6-well plates 
for 3 days at 37°C in 5% CO2. Cells were then washed, trypsinised and counted for viability by 
trypan blue exclusion. 
 
2.8 Clonogenic survival  
Cells were treated as in the viability assay, but after treatment and washing, 800-2500 cells 
were seeded in 6-well plates at 37 °C in 5% CO2 for 10-14 days. Medium was replaced every 
3 days. Colonies (>50 cells) were fixed, stained with methanol/1% crystal violet (Sigma, 1:1) 
and counted. The results were plotted as the surviving percentage relative to untreated 
values, with the latter set at 100%. 
 
2.9 Statistical analysis 
For plasmid studies, data were analysed by 2-way ANOVA. Student and paired t-tests were 
used to compare preparations at any one particular time point or the results from the oxine 
studies, respectively. Statistical analyses were carried out with GraphPad Prism 5 (version 
5.04, GraphPad Software Inc, USA). 
 
3. Results  
3.1 Cell free plasmid DNA damage by 111In and 67Ga 
Incubation of pBR322 supercoiled DNA with 111In and 67Ga (0.1-1MBq) led to single and 
double DNA strand breaks, i.e. conversion of supercoiled plasmid to either relaxed or linear 
plasmid, respectively. Plasmid integrity (i.e. the fraction of plasmid remaining in the 
supercoiled form) decreased as radioactivity increased; Figure 1A; Figure S1). As this activity 
produced significant damage without assay saturation, it was deemed suitable for 
comparative studies. DNA damage was detected as early as 4 hours post incubation (Figures 
1B-C) and after 24 hours of incubation, the supercoiled DNA fractions were reduced to 0.001 
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± 0.002 and 0.06 ± 0.01 for 67Ga and 111In respectively (p=0.002 compared to untreated). In 
contrast, untreated controls (0.76 to 0.90) and non-radioactive In-chloride (5.8 nM; 0.89 ± 
0.002) or Ga-chloride (6.9 nM; 0.86 ± 0.04) controls produced little DNA damage. 
Plasmid DNA was partially protected against 111In-induced damage, and less so from 67Ga, by 
co-incubation with DMSO (Figures 1 and S2). At 24 hours, DMSO co-incubation led to 
supercoiled fractions of 0.47 ± 0.13 and 0.20 ± 0.04, for 1 MBq 111In and 67Ga, respectively. 
External irradiation (i.e. radionuclide separated from the plasmid by the walls of a plastic 
tube; so that only gamma photons were incident upon the plasmid-containing solution) 
produced relatively little DNA damage for 67Ga (p>0.05 at 48 hours compared to untreated 
controls).  External 111In produced significantly more DNA damage than untreated controls 
(p<0.05 at 48 hours), but significantly less than internal 111In-chloride with and without 
DMSO (p<0.001 and p<0.001 at 48 hours, respectively).  
The addition of chelating agents EDTA, DTPA and citrate provided partial protection of DNA 
against damage by both radionuclides (Figures 2, S3). At 72 hours, 67Ga-chloride plus EDTA 
or DTPA (5 mM) gave a supercoiled fraction of 0.18 ± 0.05 or 0.51 ± 0.03, respectively, 
compared to 0.02 ± 0.02 for 67Ga-chloride only (Figure 2B). Similarly, 67Ga-citrate produced 
less DNA damage (supercoiled fraction: 0.72 ± 0.02) than 67Ga-chloride. Incubation with 
111In-chloride plus additional EDTA or DTPA led to supercoiled fractions of 0.27 ± 0.08 or 0.62 
± 0.05, respectively, compared to 0.02 ± 0.02 for 111In-chloride alone (Figure 2A).  
 
3.2 Radionuclide oxine synthesis 
Radiolabelling yields for 67Ga-oxine, -tropolone, and -MPO were 92%, 80%, and 25%, 
respectively, and 98% for 111In-oxine. 
 
3.3 Binding and retention of radionuclide oxine complexes 
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67Ga-oxine gave the highest cell binding (Figure S4); all subsequent studies were carried out 
with the oxine complex. In DU145 cells, a one-hour incubation with 111In-oxine or 67Ga-oxine 
allowed radionuclide binding at 60.6 ± 8.8% or 7.5 ± 1.3%, respectively (Figure 3A). This 
decreased with time with only 31.2 ± 1.4% and 38.8% ± 0.7% of the initially-bound 111In and 
67Ga, respectively, retained 72 hours after a one-hour incubation period (Figure 3B). Similar 
results were found in cell lines MDA-MB-231 and HCC1954 (Figures S5, S6). The different cell 
labelling efficiencies of 111In-oxine and 67Ga-oxine raise the issue of whether to discuss 
cellular toxicity in relation to the radioactivity to which the cells are exposed in total (i.e. the 
radioactivity added to the culture) or the radioactivity that is accumulated in the cells 
(referred to as “cell-bound” activity henceforth). Both are discussed together in the 
following paragraphs. 
 
3.4 Viability assay 
A50 is defined as the cell-bound activity causing 50% reduction in viability relative to 
untreated cells (100%). Three days after an initial one-hour incubation period with 67Ga-
oxine, the A50 was approximately 1 Bq/cell (Table 1, Figure 4A). Cell-bound 67Ga activity 
required to reduce viability to 17.4 ± 6.6% was approximately 1.5 Bq/cell; this required 
incubation with 15 MBq/mL 67Ga-oxine (Figure 4B). At this concentration, 67Ga-citrate, which 
was not taken up significantly in cells, caused only 53% loss in viability (Figure 4B). A similar 
loss in viability occurred in the control sample incubated with decayed 67Ga-oxine. 
Qualitatively similar results were obtained with 111In; the A50 was approximately 1 Bq/cell. 
However, even at cell-bound activities up to 19 Bq/cell, viability did not drop below 20%. As 
for 67Ga, the controls showed a significant level of toxicity caused by decayed 111In-oxine 
similar to that caused by 111In-chloride, which did not bind significantly to cells. Interestingly, 
67Ga-oxine-induced toxicity at 15 MBq/mL was the same as that caused by the same 
concentration of 111In-oxine, despite this concentration of 111In-oxine yielding almost 10-fold 
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higher activity per cell. Non-cell bound 111In-chloride caused toxicity (viability around 50%). A 
similar level of toxicity resulted from the purely chemical effect of decayed 111In-oxine. 
Qualitatively similar results for both 67Ga and 111In were found in cell lines MDA-MB-231 and 
HCC1954 (Figures S7 and S8 and Table S1).  
 
3.5 Clonogenic survival assay 
A one-hour incubation period with 67Ga-oxine (15 MBq/mL) with cellular uptake as little as 
1.1 Bq/cell was enough to diminish clonogenic survival to 4.4% ± 3.1% compared to 
untreated controls (Figure 5A). Replacing 67Ga-oxine with 67Ga-citrate at this same 
concentration, with minimal cellular uptake, caused no significant loss in clonogenicity 
compared to untreated controls (Figure 5B). Qualitatively similar results were obtained for 
111In demonstrating that neither radionuclide affected clonogenicity significantly unless 
bound to the cell (Figure 5B). Fully decayed radioactive 67Ga-oxine and 111In-oxine added to 
the incubation medium led to a significant decrease in relative clonogenic survival (to 74 ± 
17% and 69 ± 20% for decayed 67Ga-oxine and 111In-oxine, respectively, see Figure 5B) 
compared to untreated controls. However this chemical toxicity was much less than the 
toxicity of their non-decayed counterparts, indicating that the radioactivity was by far the 
major contributor to the observed toxic effect. Qualitatively similar results were found in cell 
lines MDA-MB-231 and HCC1954 (Figures S9 and S10 and Table S2).  
 
4. Discussion 
The plasmid data presented here suggest the involvement of different mechanisms of DNA 
damage. These include ionisation and formation of free radicals along the tracks of Auger 
electrons, local ionisation events caused directly by the residual ion after Auger electron 
emission (short range effects), free radicals diffusing significant distances from the Auger 
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electron track and residual ion, and minor ionisation and free radicals caused by gamma 
photons (long range effects). 
DNA damage produced by 67Ga was significantly reduced by chelation with EDTA, DTPA or 
citrate and incubation with hydroxyl radical scavenger DMSO. The protective effect of 
chelating the radionuclides with EDTA, DTPA or citrate, on DNA may be a distance effect; 
assuming unchelated positively-charged In3+ and Ga3+ bind directly to negatively charged 
DNA, as has previously been shown for 111In [33]. Complexing 67Ga with EDTA, forming a 
negatively charged 1:1 6-coordinate complex, would completely envelope the 67Ga atom, 
preventing metal coordination by plasmid DNA [34]. However, 111In forming a 1:1 complex 
with EDTA would leave some possibility for DNA to coordinate directly to the radiometal 
which would remain coordinatively unsaturated because of its larger ionic radius [35]. DTPA 
offers more protection then EDTA against DNA damage by 111In (Figure 2); this may be 
because being octadentate it more completely fills the coordination sphere of indium than 
EDTA does [36]. The degree of protection (EDTA<DTPA<citrate2) is also in line with the 
negative charge of the resulting complex: (1-, 2-, 5-). 
Free radical scavengers such as DMSO are unlikely to protect against the short-range effects. 
Previous studies with free radical scavengers have focused on 125I, where DMSO reduced 
strand breakage by 40% if 125I was not bound to DNA. When bound to DNA, damage induced 
by 125I was not protected by DMSO [37]. Also, non-plasmid-bound 99mTcO4- caused several 
fold lower induction of single strand breakage in the presence DMSO [38, 39]. 
Overall, direct incubation of radionuclides with plasmid DNA in a cell-free system is useful to 
understand DNA damage by radionuclide emissions and decay only. However, in these 
experiments radionuclides can directly bind DNA, thus overestimating the potential damage 
compared to the cellular environment, where direct binding to DNA is less likely.  
Results obtained in cell studies showed that 111In and 67Ga induced high clonogenic toxicity 
only if incorporated into the cell; external radionuclides and other variables had little effect. 
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Nonetheless decayed radionuclides, producing amongst other compounds zinc and 
cadmium, did influence both viability and clonogenicity. External irradiation via gamma 
emissions produced more DNA damage for 111In-chloride than 67Ga-chloride due perhaps to 
higher gamma ray exposure rate constants. Surprisingly, cell viability was decreased for non-
internalised 111In (60.9 ± 8.4%) and 67Ga (47.2 ± 8.4%) compared to untreated cells, while 
clonogenic toxicity was not. This highlights that they measure different aspects of 
cytotoxicity and are complementary rather than alternative methods. 
The clonogenic toxicity of incorporated radioactivity is similar for the two radionuclides and 
for all three cell lines, with an A10 of approximately 1 Bq/cell. This similarity should be 
interpreted cautiously, since the cellular toxicity of Auger electron emitters is likely to be 
highly dependent on the intracellular distribution of the radionuclides, which we have not 
determined and which may not be the same for the two radionuclides. Nevertheless this 
figure may be a useful guide to how much radioactivity must be incorporated into cancer 
cells in vivo for effective targeted radionuclide therapy (tRT) and could be used to assess 
feasibility of clinical tRT. 
It should be noted that 67Ga-oxine is not a very effective method of incorporating 67Ga into 
cells. Results were, however, consistent with previous trends, including radiolabeling yields 
for oxine with 67Ga [30] and cell labelling numbers of 111In-oxine [31] and 67Ga-oxine [40]. 
Efficient cell labelling with 111In is probably due to 111In-oxine diffusing into the cell 
cytoplasm and dissociating whereupon 111In binds intracellular macromolecules and is 
trapped within the cell [31]. In leukocytes, 111In-oxine also partly localises to the nucleus 
[41]. If 67Ga-oxine forms a more stable complex [40], the radionuclide may diffuse in but 
become trapped less readily due to slower dissociation. In order to achieve comparable 
cellular uptake (Bq/cell), the radioactive concentration of 67Ga-oxine was increased 
compared to 111In-oxine. 
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Future studies should focus on targeted approaches as well as in vivo therapeutic studies 
comparing 67Ga with 111In as well as beta emitters such as 177Lu. Interestingly, the higher 
energy Auger electrons emitted by 67Ga compared to other Auger electron-emitting 
radionuclides may provide an advantage by relaxing the requirement for 67Ga to be localised 
in specific sub-cellular compartments (in particular the nucleus) in order to be effective as a 
therapeutic. The critical observation that 67Ga (and similarly 111In) has to be cell bound to be 
effective suggests that future targeting studies can focus on the feasibility in vivo of 
achieving target uptake of around 1 Bq per cancer cell required for effective cell killing.  
 
5. Conclusion 
67Ga damages plasmid DNA in a manner that may be dependent on distance to the DNA, 
which in turn may be affected by the chemical form of the radionuclide. Neither 67Ga nor 
111In showed substantial toxicity unless incorporated into the cells. The threshold cellular 
uptake of 67Ga to achieve substantial cell kill is of the order of 1 Bq per cell. 67Ga deserves 
further evaluation for radionuclide therapy, especially in the context of a theranostic pairing 
with 68Ga. 
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Tables 
TABLE 1. Cell-bound activity per cell (Bq/cell) required for a 50% (A50) and 90% (A10) 
reduction in viability and clonogenicity in DU145 cells compared to untreated cells 
(determined by interpolation of data in Figures 4A and 5A). No A10 value exists for 111In-oxine 
(viability assay), as loss of membrane integrity was not achieved in more than 75% of cells. 
 
 
 
A50 (Bq/cell) A10 (Bq/cell) 
67Ga-
oxine 
111In-
oxine 
67Ga-
oxine 
111In-
oxine 
Viability  
(Trypan blue) 
1.0 1.0 1.5 N/A 
Clonogenic 0.3 0.7 1.0 0.9 
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Figures 
FIGURE 1.  
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FIGURE 2. 
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FIGURE 3.  
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FIGURE 4.  
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FIGURE 5. 
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Figure Legends 
FIGURE 1. A: Representative image of pBR322 on an agarose gel following treatment with a 
radionuclide. Here, pBR322 was incubated with 1 MBq 111In-chloride (111In-Cl3 or as external 
radiation (111In (external)) for 72 hours in the presence or absence of DMSO or cold indium 
chloride (InCl3). B and C:  Fraction of supercoiled (undamaged) plasmid, as measured from 
gels such as A. Plasmids were incubated with either 111InCl3 (B) or 67GaCl3 (C). Data points are 
average ± standard deviation (SD; n=2-3). Relaxed bands represent single strand breaks; 
linear bands are double strand breaks.  
 
FIGURE 2. Effect of chelators on plasmid damage treatd with 1 MBq 111In-chloride (A) or 
67Ga-chloride (B). The amount of supercoiled DNA (undamaged) was measured from gels 
where plasmid was incubated with the radionuclide in the presence or absence of chelators 
EDTA, DTPA and citrate for up to 72 hours. Datapoints are average ± SD (n=2-3). 
 
FIGURE 3. Cell binding (A) and retention (B) of 0.1 MBq 111In-oxine and 67Ga-oxine in 106 
DU145 cells following an initial one-hour incubation. 100% in panel B refers to the maximum 
bound radioactivity at one hour (A). Data are average ± SD (n=3/group). 
 
FIGURE 4. Viability of DU145 cells treated with 111In-oxine or 67Ga-oxine at 72 hours. A: 
Viability with increasing cell-bound activities (Bq) per cell. B: Controls for radionuclide oxine 
treatment: untreated cells, non-cell-bound radioactivity and decayed oxine complexes, 
standardised at 15 MBq/mL, inducing cellular uptake of 9.09 ± 1.33 Bq/cell for 111In-oxine 
and 1.12 ± 0.20 Bq/cell for 67Ga-oxine groups. Data are average ± SD (n=3/group). 
 
FIGURE 5. Clonogenic assay of DU145 cells treated with 111In-oxine or 67Ga-oxine. A: 
Clonogenicity with increasing cell-bound activities (Bq) per cell. B: Controls for radionuclide 
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oxine treatment: untreated cells, non-cell-bound radioactivity and decayed oxine complexes, 
standardised to treatment at 15 MBq/mL, achieving uptake of 9.09 ± 1.33 Bq/cell for 111In-
oxine and 1.12 ± 0.20 Bq/cell for 67Ga-oxine groups. Data are average ± SD (n=3/group). 
Clonogenicity for 111In-oxine at 0.28 ± 0.48% is not visible on the graph. 
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APPENDIX 
Figure S1. Imaging (A) and quantification (B) of plasmid damage assessment following 
incubation with 0.1, 0.5 and 1 MBq of 111In-chloride incubation at 4 and 24 hours. 
Supercoiled DNA refers to undamaged plasmid. Data are average ± standard deviation 
(n=3/group). 
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Figure S2. Images of plasmid following treatment with 1 MBq 67Ga-chloride (A) or 111In-
chloride (B) at 4, 24, 48 and 72 hours of incubation in the presence or absence of DMSO. 
Controls include untreated plasmid, external irradiation with 67Ga- or 111In-chloride and non-
radioactive Ga- or In- chloride and In-Cl. 
A 
 
B 
 
  
 Untreated  67Ga-Cl 67Ga-Cl + DMSO 67Ga (external) Ga-Cl 
4h 
     
      
24h 
     
      
48h 
     
      
72h 
     
 
 Untreated  111In-Cl 111In-Cl + DMSO 111In (external) In-Cl 
4h 
     
      
24h 
     
      
48h 
     
      
72h 
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Figure S3. Images of plasmid following treatment with 1 MBq 67Ga-chloride (A) or 111In-
chloride (B) at 6, 24, 48 and 72 hours of incubation in the presence or absence of chelators 
EDTA (5 mM), DTPA (5 mM) or citrate (0.9-1.7 mM).  
A 
 
B 
 
  
 Untreated Ga-67 Chloride Ga-67 EDTA Ga-67 DTPA Ga-67 Citrate 
6h 
     
      
24h 
     
      
48h 
     
      
72h 
     
 
 Untreated In-111 Chloride In-111 EDTA In-111 DTPA 
6h 
    
     
24h 
    
     
48h 
    
     
72h 
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Figure S4. Cell binding study with 67Ga-labeled lipophilic complexes, namely oxine, tropolone 
and MPO, after a one-hour incubation at 37  ͦC in 5% CO2 incubator in MDA-MB-231 cells (1 x 
106 cells/mL in 1 mL Dulbecco's PBS). Cells were pelleted and the supernatant (free activity) 
and pellets (bound) were separately measured for radioactivity using a gamma counter 
(Wallac, Germany). Data are average ± standard deviation (n=2/group).  
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Figure S5. Cell binding of 0.1 MBq 111In-oxine and 67Ga-oxine in 1 x 106 MDA-MB-231 or 
HCC1954 cells in 1 mL following an initial one-hour incubation. Data are average ± standard 
deviation (n=3/group). 
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Figure S6. Retention of 0.1 MBq 111In-oxine and 67Ga-oxine in 1 x 106 MDA-MB-231 (A) or 
HCC1954 (B) cells in 1 mL following an initial one-hour incubation. Data are average ± 
standard deviation (n=3/group). 
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Figure S7. Viability trypan blue assay of MDA-MB-231 cells (in 1 mL) following treatment 
with 111In-oxine or 67Ga-oxine (20 MBq/mL). Viability was measured at 72 hours after 
incubation of cells with the radionuclides. A: Viability with increasing activities (Bq) per cell. 
B: Controls for radionuclide oxine treatment including untreated cells, non-internalised 
radioactivity and decayed oxine complexes. Data are average ± standard deviation 
(n=3/group). 
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Figure S8. Viability trypan blue assay of HCC1954 cells (in 1 mL) following treatment with 
111In-oxine or 67Ga-oxine (20 MBq/mL). Viability was measured at 72 hours after incubation 
of cells with the radionuclides. A: Viability with increasing activities (Bq) per cell. B: Controls 
for radionuclide oxine treatment including untreated cells, non-internalised radioactivity and 
decayed oxine complexes. Data are average ± standard deviation (n=3/group). 
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Figure S9. Clonogenic assay of MDA-MB-231 cells (in 1 mL) following treatment with 111In-
oxine or 67Ga-oxine (20 MBq/mL). A: Clonogenicity i.e. surviving fraction with increasing 
activities (Bq) per cell. B: Controls for radionuclide oxine treatment including untreated cells, 
non-internalised radioactivity and decayed oxine complexes. Data are average ± standard 
deviation (n=3/group). 
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Figure S10. Clonogenic assay of HCC1954 cells (in 1 mL) following treatment with 111In-oxine 
or 67Ga-oxine (20 MBq/mL). A: Clonogenicity i.e. surviving fraction with increasing activities 
(Bq) per cell. B: Controls for radionuclide oxine treatment including untreated cells, non-
internalised radioactivity and decayed oxine complexes. Data are average ± standard 
deviation (n=3/group). 
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Table S1. Activity per cell (Bq/cell) required for a 50% and 90% reduction in viability in MDA-
MB-231 and HCC1954 cells. 
 
Cells A50 (Bq/cell) A10 (Bq/cell) 
67Ga 111In 67Ga 111In 
MDA-MB-231 1 0.5 2 - 
HCC1954 0.5 2.5 1 - 
 
 
Table S2. Activity per cell (Bq/cell) required for a 50% and 90% reduction in clonogenicity in 
MDA-MB-231 and HCC1954 cells. 
 
Cells A50 (Bq/cell) A10 (Bq/cell) 
67Ga 111In 67Ga 111In 
MDA-MB-231 0.25 0.15 1.55 0.875 
HCC1954 0.1 0.6 0.5 0.8 
 
 
